Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | FABP6 | P51161 | 2/20 | 0.36 |
| ▸ | PNP | P00491 | 2/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ULK1 | O75385 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.32 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.32 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.32 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.32 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6315467 | 0.79 | MMP12 (0.36) | PARP1FABP6PNPMMP12CDK5 | |
| SCHEMBL7416833 | 0.76 | PARP1 (0.57) | PARP1 | |
| SCHEMBL7408785 | 0.74 | PARP1 (0.57) | PARP1 | |
| SCHEMBL29728542 | 0.73 | MEN1 (0.43) | — | |
| SCHEMBL11176777 | 0.73 | NUDT1 (0.43) | PARP1CDK5CDK5R1CHEK1NUDT1 | |
| SCHEMBL7414714 | 0.72 | PARP1 (0.40) | PARP1 | |
| SCHEMBL2541920 | 0.72 | CBFB (0.49) | FABP6PNPMMP12CDK5CDK5R1 | |
| Carbamic Acid SCHEMBL6315736 | 0.71 | RPS6KA3 (0.51) | PARP1FABP6PNPMMP12CDK5 | |
| Carbamic Acid SCHEMBL6323883 | 0.71 | ALDH1A1 (0.54) | PARP1NUDT1 | |
| SCHEMBL24112331 | 0.71 | PKMYT1 (0.38) | PARP1FABP6PNPMMP12CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-09-01 | — | — | US | disclosed |
| US-6900235-B1 | Benzimidazole compounds, and pharmaceutical compositions and unit dosages thereof | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-05-31 | — | — | US | disclosed |
| US-6864275-B1 | Anticancer agents; viricides | UAF TECHNOLOGIES AND RESEARCH, LLC (US) | 2005-03-08 | — | — | US | disclosed |
| US-6710065-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER OR A VIRAL INFECTION | UAF TECHNOLOGIES AND RESEARCH, LLC | 2004-03-23 | — | — | US | disclosed |
| US-6482843-B1 | Compounds and methods for use thereof in the treatment of cancer or viral infections | THE PROCTER & GAMBLE COMPANY | 2002-11-19 | — | — | US | disclosed |
| US-6423735-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTER & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6423736-B1 | ADMINISTERING BENZIMIDAZOLE COMPOUND | THE PROCTOR & GAMBLE COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-6420411-B1 | BENZIMIDAZOLE DERIVATIVES USED TO TREAT MELANOMA, LEUKEMIA, AND COLON, BREAST, LUNG, PANCREATIC, OVARIAN, AND PROSTATE CANCER; USED TO TREAT HIV; IMPROVED WATER SOLUBILITY | THE PROCTER & GAMBLE COMPANY | 2002-07-16 | — | — | US | disclosed |
| US-6407131-B1 | 5-CARBONYLOXY-1H-BENZIMIDAZOLE-2-CARBAMATE DERIVATIVES | THE PROCTER & GAMBLE COMPANY | 2002-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192328-A1 | Compounds and methods for use thereof in the treatment of viral infections | PAICS, PIGO, BAD | PARP1 1133/4885FABP6 1633/4885PNP 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.